• Illumina Reacts to GRAIL Acquisition Ruling, AstraZeneca, Moffitt Cancer Center Partnership, 10x Genomics Platforms Mentioned, More

    Bio-IT World | Illumina welcomed the European Court of Justice's judgment ruling that the European Commission did not have jurisdiction over Illumina's acquisition of GRAIL; Moffitt Cancer Center announced a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen receptor T cell and T cell receptor therapies; 10x Genomics’ Chromium Single Cell Gene Expression and Xenium In Situ platforms in publication; and more.

    Sep 25, 2024

  • A Pill That Triggers a Desire to Exercise? Maybe... For Now, Just Go to the Gym

    Bio-IT World | What Wegovy has done for people who want to lose weight but dislike the work involved might one day find its match with a pill that pumps up a person’s desire to exercise—all by adjusting their level of interleukin 15 (IL-15), a cytokine that in the brain stimulates locomotor activity. At least that’s one of the promising possibilities dredged up by a study in mice finding a muscle-brain pathway controlling “eagerness to train more when we exercise."

    Sep 24, 2024

  • The Rise and Importance of Population-Scale Genome Programs

    Bio-IT World | With the wealth of population-scale projects going on, we have entered a golden age of genomics. Based on efforts such as the All of Us program in the U.S. and the UK Biobank, among many others, we are poised to discover more than we ever knew about natural genetic diversity, what’s considered “normal” human biology, and the continuum of health and disease.

    Sep 20, 2024

  • 2025 Bio-IT World Innovative Practices Awards Call for Entries

    Bio-IT World | Bio-IT World is accepting entries for the 2025 Innovative Practices Awards, a competition designed to recognize the most exciting partnerships and projects pushing the life sciences industry forward.

    Sep 18, 2024

  • NVIDIA Bundles NIMs for GenAI Drug Target Screening

    Bio-IT World | Last June, NVIDIA launched NIM—NVIDIA Inference Microservices—a simple, standardized way to add generative AI to applications. Now the company has released the NIM Agent Blueprint for generative AI-based virtual screening. In a blog post announcing the news, NVIDIA describes a NIM Agent Blueprint as integrated NIMs that build a workflow.

    Sep 17, 2024

  • ‘Dancing Molecules’ Could Be the Key to Cartilage Regeneration

    Bio-IT World | Osteoarthritis affects more than 528 million people around the world. Cartilage in joints wears down, and bones rub against each other, causing pain, stiffness, and mobility issues. Current treatments slow down cartilage degeneration, though patients inevitably need expensive joint replacement surgery. However, researchers at Northwestern University discovered “dancing molecules” that might be the key to the first cartilage regenerative therapy.

    Sep 12, 2024

  • AI and Biotechnology: Navigating Opportunities and Risks in the Bioeconomy

    Bio-IT World | Last month’s Bioprocessing Venture, Innovation, and Partnering Conference brought together thought leaders from across the bioeconomy to discuss the rapidly evolving landscape of artificial intelligence (AI) in biotechnology.

    Sep 11, 2024

  • Researchers Add ‘New Piece to the Puzzle’ That is Celiac Disease

    Bio-IT World | Celiac disease is a surprisingly common but substantially underdiagnosed autoimmune disorder estimated to affect 1 in 100 people globally. Left untreated, it can have “serious clinical consequences” for patients, including malnutrition, bone weakening, and potentially even a higher risk of certain cancers.

    Sep 10, 2024

  • Biotech’s Secret to Surviving Economic Challenges? It’s All in the Data & AI

    Bio-IT World | Data has always been crucial in the life sciences industry, but in today's fiercely competitive landscape, its significance has skyrocketed. Amidst dwindling funding and mounting market pressures, biopharmaceutical companies need to better harness the power of information to design and accelerate clinical trials and timelines.

    Sep 6, 2024

  • Amgen’s AI Futures: Digital Twins, Unstructured Data, Human Review

    Bio-IT World | Jerry Murry, senior vice president, process and development, at Amgen, gave the plenary presentation at CHI’s Bioprocessing Summit last month. With an eighteen-year tenure at Amgen—and experience at Merck and Pfizer before that—Murry has seen nearly two decades of advances in the world of bioprocessing and manufacturing.

    Sep 3, 2024

  • NIH Launches Native Collective Research Effort Focused on Overdose

    Bio-IT World | In August, the National Institutes of Health (NIH) has launched the Native Collective Research Effort to Enhance Wellness (N CREW) Program, an effort support Native American communities to lead public health research to address overdose, substance use, and pain, including related factors such as mental health and wellness. The planned program funding totals approximately $268 million over seven years.

    Sep 3, 2024

  • Follow the Money: AI-Powered Cell Therapies, Cancer Risk Assessment, More

    Bio-IT World | Outpace Bio will advance multiple programmed T cell product candidates to early clinical proof-of-concept for the treatment of solid tumors; Foresight Diagnostics plans to accelerate the clinical development and commercialization of their cancer recurrence testing platform, PhasED-Seq; PreciseDx plan to expand commercialization efforts for PreciseBreast risk assessment, an AI-Powered test used to assess early-stage invasive breast cancer risk; and more.

    Aug 29, 2024

  • Dovetail Genomics, Goenomics GmbH Partnership, Danaher Acquires Genedata, Andelyn Biosciences License Agreement With Broad Institute, More

    Bio-IT World |Dovetail Genomics has formed a partnership with Goenomics GmbH to deliver an enhanced genome assembly service with the fastest turnaround time and most complete annotation available in the industry; Genedata has been acquired by Danaher; Andelyn Biosciences has entered into a License Agreement with the Broad Institute of MIT and Harvard to expand its AAV Curator Platform offering to include MyoAAV plasmids; and more.

    Aug 28, 2024

  • Panel Explores the Rapidly Evolving Field of Genetic Medicines

    Bio-IT World | In a panel discussion at last week’s Bioprocessing Summit, four leaders in genetic medicine shared insights into the rapidly evolving world of gene editing and its potential to revolutionize the treatment of complex diseases. In a panel discussion at last week’s Bioprocessing Summit, four leaders in genetic medicine shared insights into the rapidly evolving world of gene editing and its potential to revolutionize the treatment of complex diseases.

    Aug 27, 2024

  • The Art of Building Techbio Teams

    Bio-IT World | The biotech industry is experiencing a significant shift as technology and biology converge. This intersection, often called Techbio, is opening up new possibilities for addressing health and environmental challenges.

    Aug 23, 2024

  • First Clinical Trial of ‘Paradoxical Intervention’ for Cancer to Begin Soon

    Bio-IT World | Cancer cells are “not like superheroes that have no vulnerabilities." Most current therapies try to block the signaling to prevent cancer’s uncontrolled division, but inevitably tumor cells resist the blockage and become far less responsive to subsequent therapy.

    Aug 21, 2024

  • Mice Cleared of Senescent Cells Shown to Die Healthier—Not Just Live Longer

    Bio-IT World | By treating a particular brand of senescent cells, it is now possible to live healthier for longer—at least in mice. If the findings can be translated to humans, that could mean an extra decade of healthiness. Plenty of medicines are already available to help people live longer, but not necessarily with vitality.

    Aug 20, 2024

  • Standardized R&D Data Exchange is Here. Let’s Embrace It.

    Bio-IT World | Life sciences companies have spent much time and treasure working to streamline and improve product development. The drivers have been many, but two have stood out. The first is a desire to improve efficiency and optimize cost, because it’s good for business and the pocketbooks of patients we ultimately serve. The second is to boost material traceability, because product quality depends on it—and regulators demand it.

    Aug 16, 2024

  • A Skeptic Converts: Tom Plasterer’s move from Big Pharma to AI Startup

    Bio-IT World | For more than a dozen years, Tom Plasterer has held roles at AstraZeneca both in research IT and in more science-facing positions including translational medicine. Along the way, he was beating the drum for FAIR data—data that are Findable, Accessible, Interoperable and Reusable— and knowledge graphs, playing an active role in both the FAIR community and the Pistoia Alliance.

    Aug 14, 2024

  • Safe and Intriguing ‘Nature’s Drugs’ Taking on Complex Diseases

    Bio-IT World | The cost of bringing a drug to market has, by some estimates, ballooned to $3 billion and the central problem could be the “misapplication of technology.” Since completion of the Human Genome Project, the focus had shifted heavily toward orphan drugs with a single genetic target, suitable only to highly targeted genetic technology platforms.

    Aug 13, 2024